Skip to main content

CACZ885U2301 A randomized, double-blind, placebo-controlled, phase III study evaluating the efficacy and safety of pembrolizumab plus platinum-based doublet chemotherapy with or without canakinumab as first line therapy for locally advanced or metastatic

NCT03631199

A randomized, double-blind, placebo-controlled, phase III study evaluating the efficacy and safety of pembrolizumab plus platinum-based doublet chemotherapy with or without canakinumab as first line therapy for locally advanced or metastatic non-squamous and squamous non-small cell lung cancer subjects (CANOPY-1)

Associated Conditions

Lung Cancer

Principal Investigator

Sponsor

CACZ885U2301 Novartis Study Team

The purpose of the study is to evaluate how safe and effective canakinumab in combination with other drugs (pembrolizumab and platinum-based doublet chemotherapy) already commonly used to treat lung cancer is. The purpose is also to understand how your body reacts to the study treatment (e.g., absorbs, distributes) in order to understand the effect of this combination, if any, on your cancer and to study biomarkers (proteins present in your blood and tumor tissue).